|
|
-
DOYLESTOWN, PA – June 9, 2010 – QuantRx® Biomedical Corporation (OTCBB: QTXB), a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, today announced that it has completed clinical testing of the Q-Reader™ thyroid testing system. QuantRx Biomedical Corporation is pleased to be at this regulatory stage, which follows the completion of studies showing that the innovative Q-Reader thyroid testing system is capable of providing healthcare practitioners with laboratory level quantitative results within minutes, rather than waiting for results to be returned from a commercial laboratory.
-
DOYLESTOWN, PA – May 7, 2010 – QuantRx® Biomedical Corporation (OTCBB:QTXB), a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, today announced that it has entered into a two-year agreement with VetRed BV for the European distribution of products developed by QuantRx (QN Diagnostics) for veterinary applications. This is the first distribution agreement for QuantRx (QN Diagnostics) in the animal healthcare market and marks the commercial launch of its first product developed for the segment.
-
DOYLESTOWN, PA – May 6, 2010 – QuantRx® Biomedical Corporation (OTCBB:QTXB), an emerging leader in the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide point-of-care healthcare industry, today announced the appointment of two new independent directors to its Board of Directors; one of the appointments is a replacement for the seat vacated by Arthur Hull Hayes, Jr., M.D., who died earlier this year.
-
DOYLESTOWN, PA – February 16, 2010 – QuantRx® Biomedical Corporation (OTCBB:QTXB), an emerging leader in the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide point-of-care healthcare industry, today announced that its proprietary PadKit has been selected as the sample collection system by the UCLA School of Nursing for a comparative cytology study of cervical cancer. Led by UCLA School of Nursing Associate Professor Dr. Dorothy Wiley, the study is funded by an initial grant from the UCLA School of Nursing and intended to identify a low cost diagnostic solution for cervical cancer screening in resource-poor areas.
|
If you are a stockholder and wish to be added to our electronic mailing list, please email us your name and current email address to receive updates and the latest press releases. |
|
-
DOYLESTOWN, PA – January 29, 2010 -- QuantRx Biomedical Corporation (OTCBB: QTXB) today announced that it has entered into an agreement to acquire NuRx Pharmaceuticals, Inc. (OTCBB: NUXP). The transaction is structured as a tax-free, all stock acquisition resulting in a combined company with no debt and a simplified ownership and capital structure. QuantRx expects to benefit from a strengthened competitive and financial position to accelerate efforts to capitalize on opportunities in the growing market for Point-of-Care diagnostic products.
-
DOYLESTOWN, PA – January 19, 2010 -- QuantRx® Biomedical Corporation (OTCBB: QTXB), a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, today provided an update from Chairman and Chief Executive Officer Walter Witoshkin on its involvement in genetics-based personalized medicine and disease prevention.
-
DOYLESTOWN, PA – January 11, 2010 -- QuantRx® Biomedical Corporation (OTCBB: QTXB), a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, announced today that Walter Witoshkin, Chairman and Chief Executive Officer, will present at the OneMedForum 2010 Emerging Company Finance Conference in San Francisco, CA, on Wednesday, January 13, 2010.
|
|
 |
